| Shane Reynolds, DPM | |
|
488 Main Ave, Norwalk, CT 06851-1008 | |
| (203) 838-0442 | |
| Not Available |
| Full Name | Shane Reynolds |
|---|---|
| Gender | Male |
| Speciality | Podiatry |
| Experience | 9 Years |
| Location | 488 Main Ave, Norwalk, Connecticut |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1780079269 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 213E00000X | Podiatrist | 001009 (Connecticut) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Norwalk Hospital | Norwalk, CT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Devang C Patel Pc | 4587740576 | 2 |
News Archive
Medtronic, Inc. today announced the U.S. Food and Drug Administration (FDA) has classified the company's previous action related to the Octopus® Nuvo Tissue Stabilizer as a Class I recall. FDA classifies a recall as Class I when the agency believes that there is a reasonable probability that use of the recalled product will cause serious adverse health consequences or death. On Sept. 14, 2010, Medtronic proactively and voluntarily recalled the device from the market due to the potential that a component of the device could fracture during use.
Already pioneers in the use of immunotherapy, City of Hope researchers are now testing the bold approach to cancer treatment against one of medicine's biggest challenges: brain cancer. This month, they will launch a clinical trial using patients' own modified T cells to fight advanced brain tumors.
Advanced Cell Technology, Inc., a biotechnology company applying cellular technology in the field of regenerative medicine, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for the company's MA09-hRPE cells for use in the treatment of Stargardt's Macular Dystrophy (SMD). As a result, the company is eligible to receive a number of benefits, including tax credits, access to grant funding for clinical trials, accelerated FDA approval and allowance for marketing exclusivity after drug approval for a period of as long as seven years.
A groundbreaking new test for male infertility, which will save time, money and heartache for couples around the world, has been developed at Queen's University Belfast.
From discovering how text messages can help build empathy to figuring out how character and personality affect ethical behavior on the job, the Character Project at Wake Forest University has led to remarkable advances in the study of human nature, values, morals and decision-making.
› Verified 8 days ago
| Provider Name | Norwalk Hospital Association |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1427041581 PECOS PAC ID: 3375436660 Enrollment ID: O20040202000988 |
News Archive
Medtronic, Inc. today announced the U.S. Food and Drug Administration (FDA) has classified the company's previous action related to the Octopus® Nuvo Tissue Stabilizer as a Class I recall. FDA classifies a recall as Class I when the agency believes that there is a reasonable probability that use of the recalled product will cause serious adverse health consequences or death. On Sept. 14, 2010, Medtronic proactively and voluntarily recalled the device from the market due to the potential that a component of the device could fracture during use.
Already pioneers in the use of immunotherapy, City of Hope researchers are now testing the bold approach to cancer treatment against one of medicine's biggest challenges: brain cancer. This month, they will launch a clinical trial using patients' own modified T cells to fight advanced brain tumors.
Advanced Cell Technology, Inc., a biotechnology company applying cellular technology in the field of regenerative medicine, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for the company's MA09-hRPE cells for use in the treatment of Stargardt's Macular Dystrophy (SMD). As a result, the company is eligible to receive a number of benefits, including tax credits, access to grant funding for clinical trials, accelerated FDA approval and allowance for marketing exclusivity after drug approval for a period of as long as seven years.
A groundbreaking new test for male infertility, which will save time, money and heartache for couples around the world, has been developed at Queen's University Belfast.
From discovering how text messages can help build empathy to figuring out how character and personality affect ethical behavior on the job, the Character Project at Wake Forest University has led to remarkable advances in the study of human nature, values, morals and decision-making.
› Verified 8 days ago
| Provider Name | Michael Z Fein Dpm Pc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1366513434 PECOS PAC ID: 5395799332 Enrollment ID: O20050311000457 |
News Archive
Medtronic, Inc. today announced the U.S. Food and Drug Administration (FDA) has classified the company's previous action related to the Octopus® Nuvo Tissue Stabilizer as a Class I recall. FDA classifies a recall as Class I when the agency believes that there is a reasonable probability that use of the recalled product will cause serious adverse health consequences or death. On Sept. 14, 2010, Medtronic proactively and voluntarily recalled the device from the market due to the potential that a component of the device could fracture during use.
Already pioneers in the use of immunotherapy, City of Hope researchers are now testing the bold approach to cancer treatment against one of medicine's biggest challenges: brain cancer. This month, they will launch a clinical trial using patients' own modified T cells to fight advanced brain tumors.
Advanced Cell Technology, Inc., a biotechnology company applying cellular technology in the field of regenerative medicine, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for the company's MA09-hRPE cells for use in the treatment of Stargardt's Macular Dystrophy (SMD). As a result, the company is eligible to receive a number of benefits, including tax credits, access to grant funding for clinical trials, accelerated FDA approval and allowance for marketing exclusivity after drug approval for a period of as long as seven years.
A groundbreaking new test for male infertility, which will save time, money and heartache for couples around the world, has been developed at Queen's University Belfast.
From discovering how text messages can help build empathy to figuring out how character and personality affect ethical behavior on the job, the Character Project at Wake Forest University has led to remarkable advances in the study of human nature, values, morals and decision-making.
› Verified 8 days ago
| Provider Name | Devang C Patel Pc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1417134693 PECOS PAC ID: 4587740576 Enrollment ID: O20080401000360 |
News Archive
Medtronic, Inc. today announced the U.S. Food and Drug Administration (FDA) has classified the company's previous action related to the Octopus® Nuvo Tissue Stabilizer as a Class I recall. FDA classifies a recall as Class I when the agency believes that there is a reasonable probability that use of the recalled product will cause serious adverse health consequences or death. On Sept. 14, 2010, Medtronic proactively and voluntarily recalled the device from the market due to the potential that a component of the device could fracture during use.
Already pioneers in the use of immunotherapy, City of Hope researchers are now testing the bold approach to cancer treatment against one of medicine's biggest challenges: brain cancer. This month, they will launch a clinical trial using patients' own modified T cells to fight advanced brain tumors.
Advanced Cell Technology, Inc., a biotechnology company applying cellular technology in the field of regenerative medicine, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for the company's MA09-hRPE cells for use in the treatment of Stargardt's Macular Dystrophy (SMD). As a result, the company is eligible to receive a number of benefits, including tax credits, access to grant funding for clinical trials, accelerated FDA approval and allowance for marketing exclusivity after drug approval for a period of as long as seven years.
A groundbreaking new test for male infertility, which will save time, money and heartache for couples around the world, has been developed at Queen's University Belfast.
From discovering how text messages can help build empathy to figuring out how character and personality affect ethical behavior on the job, the Character Project at Wake Forest University has led to remarkable advances in the study of human nature, values, morals and decision-making.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Shane Reynolds, DPM 488 Main Ave, Norwalk, CT 06851-1008 Ph: (203) 838-0442 | Shane Reynolds, DPM 488 Main Ave, Norwalk, CT 06851-1008 Ph: (203) 838-0442 |
News Archive
Medtronic, Inc. today announced the U.S. Food and Drug Administration (FDA) has classified the company's previous action related to the Octopus® Nuvo Tissue Stabilizer as a Class I recall. FDA classifies a recall as Class I when the agency believes that there is a reasonable probability that use of the recalled product will cause serious adverse health consequences or death. On Sept. 14, 2010, Medtronic proactively and voluntarily recalled the device from the market due to the potential that a component of the device could fracture during use.
Already pioneers in the use of immunotherapy, City of Hope researchers are now testing the bold approach to cancer treatment against one of medicine's biggest challenges: brain cancer. This month, they will launch a clinical trial using patients' own modified T cells to fight advanced brain tumors.
Advanced Cell Technology, Inc., a biotechnology company applying cellular technology in the field of regenerative medicine, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for the company's MA09-hRPE cells for use in the treatment of Stargardt's Macular Dystrophy (SMD). As a result, the company is eligible to receive a number of benefits, including tax credits, access to grant funding for clinical trials, accelerated FDA approval and allowance for marketing exclusivity after drug approval for a period of as long as seven years.
A groundbreaking new test for male infertility, which will save time, money and heartache for couples around the world, has been developed at Queen's University Belfast.
From discovering how text messages can help build empathy to figuring out how character and personality affect ethical behavior on the job, the Character Project at Wake Forest University has led to remarkable advances in the study of human nature, values, morals and decision-making.
› Verified 8 days ago
Harris A Greenberger, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 4 Colony St, Norwalk, CT 06851 Phone: 203-866-3377 | |
Dr. Lonnie Neil Resnick Ix, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 83 East Ave, Ste 313, Norwalk, CT 06851 Phone: 203-853-6570 Fax: 203-853-2078 | |
Dr. Marisa Kim Dematteo-santa, D.P.M. Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 488 Main Ave, Norwalk, CT 06851 Phone: 203-838-0442 Fax: 203-838-9431 | |
Best Podiatry, Llc Podiatrist Medicare: Medicare Enrolled Practice Location: 40 Cross St Ste 330, Norwalk, CT 06851 Phone: 203-984-1885 | |
Fairfield County Foot Surgeons Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 4 Colony St, Norwalk, CT 06851 Phone: 203-866-3377 Fax: 203-866-5599 | |
Marvin Ginsberg, D.p.m. Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 111 East Ave, Suite 317, Norwalk, CT 06851 Phone: 203-853-7282 Fax: 203-853-3050 | |
Arch Foot Care Podiatrist Medicare: Medicare Enrolled Practice Location: 488 Main Ave, Norwalk, CT 06851 Phone: 203-721-7861 |